Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV1FGF in Severe Peripheral Artery Occlusive Disease
NCT00368797Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2002
- Primary completion
- Apr 2005
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of Riferminogene pecaplasmid in critical limb ischemia (CLI), sponsored by Sanofi. Started Mar 2002; status: completed.
02
Drugs
Riferminogene pecaplasmid
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT00368797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368797.